MX2023010175A - Antagonistas de canales de calcio tipo t y usos de los mismos. - Google Patents

Antagonistas de canales de calcio tipo t y usos de los mismos.

Info

Publication number
MX2023010175A
MX2023010175A MX2023010175A MX2023010175A MX2023010175A MX 2023010175 A MX2023010175 A MX 2023010175A MX 2023010175 A MX2023010175 A MX 2023010175A MX 2023010175 A MX2023010175 A MX 2023010175A MX 2023010175 A MX2023010175 A MX 2023010175A
Authority
MX
Mexico
Prior art keywords
calcium channel
type calcium
channel antagonists
cell
antagonists
Prior art date
Application number
MX2023010175A
Other languages
English (en)
Spanish (es)
Inventor
Robert Zahler
David Nguyen
Xinnan Wang
Roeland Vanhauwaert
Vinita Bharat
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2023010175A publication Critical patent/MX2023010175A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2023010175A 2021-03-04 2022-03-03 Antagonistas de canales de calcio tipo t y usos de los mismos. MX2023010175A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163156806P 2021-03-04 2021-03-04
US202163228505P 2021-08-02 2021-08-02
PCT/US2022/018682 WO2022216386A2 (en) 2021-03-04 2022-03-03 T-type calcium channel antagonists and uses thereof

Publications (1)

Publication Number Publication Date
MX2023010175A true MX2023010175A (es) 2023-09-07

Family

ID=83545681

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010175A MX2023010175A (es) 2021-03-04 2022-03-03 Antagonistas de canales de calcio tipo t y usos de los mismos.

Country Status (10)

Country Link
US (1) US20240190865A1 (cg-RX-API-DMAC7.html)
EP (1) EP4301759A4 (cg-RX-API-DMAC7.html)
JP (1) JP7884740B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230167035A (cg-RX-API-DMAC7.html)
AU (1) AU2022255225A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023016601A2 (cg-RX-API-DMAC7.html)
CA (1) CA3208202A1 (cg-RX-API-DMAC7.html)
IL (1) IL305381A (cg-RX-API-DMAC7.html)
MX (1) MX2023010175A (cg-RX-API-DMAC7.html)
WO (1) WO2022216386A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024081653A2 (en) * 2022-10-12 2024-04-18 Acurex Biosciences Corporation Methods of lowering miro2 to treat neurodegenerative diseases
US20260174741A1 (en) * 2022-10-31 2026-06-25 Acurex Biosciences Corporation Methods of reducing miro1 or phosphorylated alpha-synuclein
CN116813444A (zh) * 2023-06-28 2023-09-29 福建凯昕药业有限公司 一种1-溴-4-(1-(三氟甲基)环丙基)苯的制备方法
IT202400013555A1 (it) * 2024-06-13 2025-12-13 Iama Therapeutics S R L Derivati benzoimidazolici come inibitori di nkcc1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610701B2 (en) * 2001-02-09 2003-08-26 Merck & Co., Inc. Thrombin inhibitors
US7875636B2 (en) * 2006-04-12 2011-01-25 Merck Sharp & Dohme Corp. Pyridyl amide T-type calcium channel antagonists
KR20100072266A (ko) * 2007-10-24 2010-06-30 머크 샤프 앤드 돔 코포레이션 헤테로사이클 페닐 아미드 t-형 칼슘 채널 길항제
CA2702126A1 (en) * 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Heterocycle amide t-type calcium channel antagonists
US8987310B2 (en) * 2009-10-30 2015-03-24 Merck Sharp & Dohme Corp. Heterocycle amide T-type calcium channel antagonists
CN114929242A (zh) * 2019-09-05 2022-08-19 小利兰·斯坦福大学托管委员会 修饰线粒体功能的方法和化合物

Also Published As

Publication number Publication date
WO2022216386A9 (en) 2022-12-01
JP7884740B2 (ja) 2026-07-06
US20240190865A1 (en) 2024-06-13
JP2024508903A (ja) 2024-02-28
WO2022216386A3 (en) 2023-01-12
CA3208202A1 (en) 2022-10-13
WO2022216386A2 (en) 2022-10-13
EP4301759A4 (en) 2025-09-24
EP4301759A2 (en) 2024-01-10
IL305381A (en) 2023-10-01
KR20230167035A (ko) 2023-12-07
AU2022255225A1 (en) 2023-09-21
BR112023016601A2 (pt) 2023-12-12

Similar Documents

Publication Publication Date Title
BR112023016601A2 (pt) Antagonistas do canal de cálcio tipo t e usos dos mesmos
IL282774A (en) Expansion of tils utilizing akt pathway inhibitors
PL3844830T3 (pl) Katoda i urządzenie elektrochemiczne
IL283342A (en) Electrochemical devices and fuel cell systems
CO2022008969A2 (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CL2022000027A1 (es) Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257).
CL2021000651A1 (es) Técnicas para gestión de espacio de búsqueda
MXPA04001501A (es) Reduccion de interferencia en un sistema de comunicacion duplex con division de tiempo que usa acceso multiple con division de codigo.
CL2015002871A1 (es) Derivados de bencimidazolona como inhibidores del bromodominio
MX2018003703A (es) Metodo y sistema que utiliza una diferencia de correlacion a largo plazo entre canales izquierdo y derecho para la mezcla descendente del dominio de tiempo a una señal sonora estereo en canales primario y secundario.
CO2023012821A2 (es) Anticuerpos anti-nectina-4 y usos de los mismos
CO5271708A1 (es) Ensayo y metodos basados en el uso de canales de sodio como objetivos de amiloide b o de sus agregados
AR066335A1 (es) Uso de elastomeros para producir geles para tratar una luz de pozo
MX2022005293A (es) Paneles de hormigon aislante pretensado y metodos para fabricar y utilizar los mismos.
EP4113730A4 (en) COIN-SHAPED SECONDARY CELL
CL2020001480A1 (es) Métodos para obtener células derivadas de músculo.
CL2023003613S1 (es) Batería.
EP4130145A4 (en) MIXTURE OF ELECTRODE, ELECTRODE AND RECHARGEABLE BATTERY
EP4037068A4 (en) SET OF ELECTRODES AND SECONDARY BATTERY INCLUDING SAME
EP4485681A4 (en) Electrolyte injection device
MX2024011232A (es) Inhibidores de tyk2 y usos de los mismos
CL2021003127A1 (es) Durmientes ferroviarios y métodos de los mismos.
EP4210133A4 (en) ELECTRODE MIXTURE, SECONDARY BATTERY AND COMPOSITION
EP4368204A4 (en) Use of spore of clostridium ghonii in combination with pembrolizumab
EP4340056A4 (en) MIXTURE OF POSITIVE ELECTRODE, POSITIVE ELECTRODE, AND SECONDARY BATTERY